 Brooks Hybertson
Concepts (101)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| NF-E2-Related Factor 2 | 5 | 2022 | 71 | 1.060 |
Why?
| | Oxidative Stress | 2 | 2019 | 1068 | 0.360 |
Why?
| | alpha-Tocopherol | 1 | 2005 | 25 | 0.240 |
Why?
| | Lung | 3 | 2005 | 3521 | 0.220 |
Why?
| | Proteostasis | 1 | 2022 | 20 | 0.200 |
Why?
| | Antioxidants | 2 | 2019 | 529 | 0.200 |
Why?
| | Lipopolysaccharides | 1 | 2005 | 813 | 0.190 |
Why?
| | Transforming Growth Factor beta | 1 | 2003 | 445 | 0.180 |
Why?
| | Cistaceae | 1 | 2020 | 1 | 0.180 |
Why?
| | Pneumonia | 2 | 2005 | 563 | 0.180 |
Why?
| | Isoniazid | 3 | 2006 | 52 | 0.180 |
Why?
| | tat Gene Products, Human Immunodeficiency Virus | 1 | 2019 | 20 | 0.160 |
Why?
| | Interleukin-1 | 1 | 2003 | 965 | 0.160 |
Why?
| | Alveolar Epithelial Cells | 1 | 2019 | 93 | 0.150 |
Why?
| | Macrophages, Alveolar | 3 | 2006 | 348 | 0.150 |
Why?
| | Altitude | 1 | 2020 | 435 | 0.130 |
Why?
| | Rats, Sprague-Dawley | 6 | 2006 | 2182 | 0.120 |
Why?
| | Bronchoalveolar Lavage Fluid | 4 | 2005 | 580 | 0.120 |
Why?
| | HIV Infections | 2 | 2019 | 2453 | 0.120 |
Why?
| | Chemokines, CXC | 2 | 2005 | 60 | 0.110 |
Why?
| | Drug Delivery Systems | 3 | 2005 | 295 | 0.110 |
Why?
| | Ferritins | 2 | 2004 | 52 | 0.110 |
Why?
| | HIV-1 | 1 | 2019 | 768 | 0.110 |
Why?
| | Rats | 7 | 2006 | 4913 | 0.110 |
Why?
| | MicroRNAs | 1 | 2019 | 600 | 0.100 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2005 | 347 | 0.100 |
Why?
| | Antitubercular Agents | 2 | 2005 | 169 | 0.100 |
Why?
| | Drugs, Chinese Herbal | 1 | 2011 | 13 | 0.100 |
Why?
| | Animals | 10 | 2022 | 31565 | 0.090 |
Why?
| | Hemorrhage | 2 | 2004 | 600 | 0.080 |
Why?
| | Neutrophils | 2 | 2005 | 1089 | 0.080 |
Why?
| | Administration, Inhalation | 2 | 2005 | 637 | 0.060 |
Why?
| | Chemokine CXCL1 | 1 | 2005 | 67 | 0.060 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2006 | 465 | 0.060 |
Why?
| | Quinacrine | 1 | 2004 | 7 | 0.060 |
Why?
| | Cell Line | 4 | 2019 | 2629 | 0.060 |
Why?
| | Tandem Mass Spectrometry | 1 | 2006 | 410 | 0.060 |
Why?
| | Cells, Cultured | 2 | 2019 | 3861 | 0.060 |
Why?
| | Recombinant Proteins | 2 | 2005 | 1228 | 0.060 |
Why?
| | Signal Transduction | 2 | 2019 | 4501 | 0.060 |
Why?
| | Genetic Therapy | 1 | 2005 | 256 | 0.060 |
Why?
| | Tissue Plasminogen Activator | 1 | 2005 | 204 | 0.060 |
Why?
| | Pulmonary Circulation | 1 | 2005 | 407 | 0.050 |
Why?
| | Microspheres | 1 | 2003 | 123 | 0.050 |
Why?
| | Trachea | 1 | 2005 | 223 | 0.050 |
Why?
| | Polyesters | 1 | 2003 | 64 | 0.050 |
Why?
| | Peroxidase | 1 | 2003 | 161 | 0.050 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2003 | 159 | 0.050 |
Why?
| | Leukocyte Count | 1 | 2003 | 292 | 0.050 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2003 | 53 | 0.050 |
Why?
| | Guinea Pigs | 1 | 2022 | 136 | 0.050 |
Why?
| | Prodrugs | 1 | 2002 | 42 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2004 | 743 | 0.050 |
Why?
| | Inflammation | 1 | 2011 | 2464 | 0.050 |
Why?
| | Reactive Oxygen Species | 2 | 2019 | 522 | 0.050 |
Why?
| | Phytochemicals | 1 | 2020 | 7 | 0.040 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2005 | 1128 | 0.040 |
Why?
| | Antioxidant Response Elements | 1 | 2019 | 5 | 0.040 |
Why?
| | Oxidoreductases Acting on Sulfur Group Donors | 1 | 2019 | 11 | 0.040 |
Why?
| | Rats, Transgenic | 1 | 2019 | 15 | 0.040 |
Why?
| | Antagomirs | 1 | 2019 | 13 | 0.040 |
Why?
| | NAD(P)H Dehydrogenase (Quinone) | 1 | 2019 | 31 | 0.040 |
Why?
| | Heme Oxygenase-1 | 1 | 2019 | 51 | 0.040 |
Why?
| | Oxygen | 1 | 2003 | 851 | 0.040 |
Why?
| | Rats, Inbred F344 | 1 | 2019 | 241 | 0.040 |
Why?
| | Plant Extracts | 1 | 2020 | 154 | 0.040 |
Why?
| | HIV | 1 | 2019 | 208 | 0.040 |
Why?
| | RNA, Messenger | 1 | 2005 | 2550 | 0.040 |
Why?
| | Antibodies, Monoclonal | 1 | 2003 | 1257 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2019 | 534 | 0.030 |
Why?
| | Mitochondria | 1 | 2022 | 744 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 295 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2019 | 917 | 0.030 |
Why?
| | Male | 6 | 2022 | 55396 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2019 | 677 | 0.030 |
Why?
| | Chemistry, Pharmaceutical | 2 | 2005 | 98 | 0.030 |
Why?
| | Muscle, Skeletal | 1 | 2022 | 1468 | 0.030 |
Why?
| | Diet | 1 | 2020 | 1080 | 0.030 |
Why?
| | Aging | 1 | 2022 | 1611 | 0.030 |
Why?
| | Humans | 4 | 2021 | 114045 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2019 | 3498 | 0.020 |
Why?
| | Enzyme Stability | 1 | 2005 | 62 | 0.020 |
Why?
| | Molecular Structure | 1 | 2006 | 434 | 0.020 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2005 | 192 | 0.020 |
Why?
| | Drug Compounding | 1 | 2005 | 89 | 0.020 |
Why?
| | Pulmonary Ventilation | 1 | 2005 | 72 | 0.020 |
Why?
| | Delayed-Action Preparations | 1 | 2005 | 158 | 0.010 |
Why?
| | Nanostructures | 1 | 2005 | 94 | 0.010 |
Why?
| | Oxidants | 1 | 2004 | 112 | 0.010 |
Why?
| | Iron, Dietary | 1 | 2003 | 19 | 0.010 |
Why?
| | Aged | 1 | 2021 | 18969 | 0.010 |
Why?
| | Leukocytes | 1 | 2004 | 272 | 0.010 |
Why?
| | Crystallization | 1 | 2003 | 136 | 0.010 |
Why?
| | Fibrinolytic Agents | 1 | 2005 | 231 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2005 | 735 | 0.010 |
Why?
| | Mass Spectrometry | 1 | 2005 | 622 | 0.010 |
Why?
| | Quaternary Ammonium Compounds | 1 | 2002 | 44 | 0.010 |
Why?
| | Ions | 1 | 2002 | 59 | 0.010 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2002 | 176 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2006 | 2764 | 0.010 |
Why?
| | Female | 1 | 2022 | 59324 | 0.010 |
Why?
|
|
Hybertson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|